Tharimmune Closes Highly Dilutive $55M Offering of Common Stock and Pre-Funded Warrants for Digital Asset Strategy

summarizeSummary

Tharimmune, Inc. closed a $55 million underwritten registered direct offering, issuing common stock and pre-funded warrants, which is highly dilutive and intended to fund its Canton-centric digital asset treasury strategy and general corporate purposes.

check_boxKey Events

• Underwritten Registered Direct Offering Closed

  Tharimmune, Inc. announced the closing of an underwritten registered direct offering on January 20, 2026.

• Significant Capital Raise

  The offering generated gross proceeds of approximately $55 million for the company.

• Highly Dilutive Issuance

  The offering included 1,800,000 shares of common stock at $2.92 per share and pre-funded warrants to purchase up to 17,000,000 shares of common stock at $2.9199 per warrant, indicating substantial dilution.

• Strategic Use of Proceeds

  Proceeds will primarily fund the continued expansion and development of the company's Canton-centric digital asset treasury strategy, as well as working capital for general corporate purposes.

auto_awesomeAnalysis

Tharimmune, Inc. has secured a substantial capital infusion of $55 million through an underwritten registered direct offering. This financing is highly dilutive, representing a significant portion of the company's current market capitalization, and includes pre-funded warrants which effectively act as common stock due to their nominal exercise price. The proceeds are earmarked for the expansion of its Canton-centric digital asset treasury strategy and general corporate purposes, indicating a strong focus on its blockchain initiatives. The offering price was at a slight discount to the current market price, and the company also disclosed prior capital raising through an ATM program, suggesting an ongoing need for funding. Investors should closely monitor the impact of this dilution on per-share metrics and the execution of the company's digital asset strategy.